Head-to-head

Retatrutide vs MOTS-c

A field-by-field comparison of Retatrutide and MOTS-c drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.

Retatrutide vs MOTS-c at a glance

Attribute	Retatrutide	MOTS-c
Category	Metabolic	Metabolic
Evidence grade	Strong	Emerging
Also known as	LY3437943, Triple G	Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide
Chain	39 amino acid triple GIP / GLP-1 / glucagon receptor agonist	16 amino acid mitochondrial-derived peptide
Mechanism	Simultaneously activates GLP-1, GIP and glucagon receptors in a single peptide. The glucagon component increases energy expenditure and hepatic lipid oxidation, while GLP-1 and GIP suppress appetite, slow gastric emptying and improve glucose-dependent insulin secretion.	Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.
Reported benefits	Up to ~24% mean weight loss at 12 mg over 48 weeks in phase 2 · Large reductions in HbA1c and liver fat · Improvements in blood pressure, triglycerides and LDL cholesterol	Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction
Reported side effects	Nausea and vomiting · Diarrhoea · Gallbladder issues · Mild resting heart-rate increase · Injection-site reaction	Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals
Half-life	About 5–7 days	Estimated minutes to a few hours
Administration	Once-weekly subcutaneous injection	Subcutaneous injection; oral capsules are marketed but less validated
Dosing overview	Phase 2 started at 2 mg weekly and escalated to 12 mg over several weeks	Commonly cited at 5–10 mg daily, often for 4–12 week cycles
Storage	Investigational product; typically refrigerated as lyophilised or pen formulation	Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days
Legal status	Investigational drug; not FDA-approved as of 2026.	Research chemical; not approved as a drug.

Key differences between Retatrutide and MOTS-c

Both are metabolic compounds

Retatrutide and MOTS-c are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Retatrutide: "A once-weekly 'triple G' agonist that produced the largest weight reductions of any incretin-class molecule in phase 2 obesity trials." MOTS-c: "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects."

Mechanism of action

Retatrutide: Simultaneously activates GLP-1, GIP and glucagon receptors in a single peptide. The glucagon component increases energy expenditure and hepatic lipid oxidation, while GLP-1 and GIP suppress appetite, slow gastric emptying and improve glucose-dependent insulin secretion. MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.

Evidence quality is not equal

Retatrutide carries a Strong evidence grade and MOTS-c a Emerging grade on this index. The grade describes the quality of published human data, not how well a compound works — Retatrutide has the better-documented record of the two, and claims made about MOTS-c rest on thinner human evidence.

Half-life and dosing frequency

Retatrutide is listed at about 5–7 days; MOTS-c at estimated minutes to a few hours. That difference is what drives the reported schedules: Phase 2 started at 2 mg weekly and escalated to 12 mg over several weeks versus Commonly cited at 5–10 mg daily, often for 4–12 week cycles

Route of administration

Retatrutide is administered by once-weekly subcutaneous injection. MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated.

Legal and regulatory status differs

Retatrutide: Investigational drug; not FDA-approved as of 2026. MOTS-c: Research chemical; not approved as a drug. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

Retatrutide is stored investigational product; typically refrigerated as lyophilised or pen formulation. MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days.

What Retatrutide and MOTS-c have in common

Category: both listed as Metabolic

Each compound in brief

Retatrutide

Metabolic · Strong evidence

A once-weekly 'triple G' agonist that produced the largest weight reductions of any incretin-class molecule in phase 2 obesity trials.

Considerations: Still investigational; long-term cardiovascular and safety data are pending · Muscle-loss and GI tolerability concerns mirror semaglutide and tirzepatide · Dose must be escalated slowly to improve tolerability

MOTS-c

Metabolic · Emerging evidence

A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.

Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection

Retatrutide vs MOTS-c